Nalaganje...
Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)
The Bruton tyrosine kinase inhibitor (BTKi) ibrutinib is a new targeted therapy for patients with chronic lymphocytic leukemia (CLL). Ibrutinib is given orally on a continuous schedule and induces durable remissions in the majority of CLL patients. However, a small proportion of patients initially r...
Shranjeno v:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
National Academy of Sciences
2014
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4183279/ https://ncbi.nlm.nih.gov/pubmed/25201956 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1409362111 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|